GLS and breast carcinoma: In addition, other research groups have also demonstrated the potential of (2S,4R)4-[18F]fluoroglutamine ([18F]4F-Gln) in tracking cellular glutamine pool size in breast cancers with differential glutaminase (GLS) activity and detecting increases in cellular glutamine pool size induced by GLS inhibitors [45,46].